Abstracts tagged "Behçet’s Syndrome"

Abstract Number: 2519 • ACR Convergence 2023
A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease
Charles Jones¹, Zhanguo Li², Zhuoli Zhang³, Jian Wu⁴, Guixiu Shi⁵, Wenjie Zheng⁶, Jianping Tang⁷, Xiaobing Wang⁸, Lie Dai⁹, Lin Chen¹⁰, Yasong Li¹¹, Ling Wu¹², Yongfu Wang¹³, Shengyun Liu¹⁴, Yao Ke¹⁵, Jin Lin¹⁶, Zhenchun Zhang¹⁷, Jiankang Hu¹⁸, Wantai Dang¹⁹, Songlou Yin²⁰, Xin Tang²¹, Mingfei Zhu²², Jinfeng Lin²², Richard Jones²², Weiguo Wan²³ and xianjun Hu²², ¹Hemay Pharmaceuticals, Tianjin, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, ³Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ⁴Suzhou University Affiliated First Hospital, Suzhou, China, ⁵the First Affiliated Hospital of Xiamen University, Xiamen, China, ⁶Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ⁷Shanghai Tongji Hospital, Shanghai, China, ⁸The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁹Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, ¹⁰Jilin Provincial People's Hospital, Changchun, China, ¹¹11Zhejiang Provincial People's Hospital, Hangzhou, China, ¹²University of Hong Kong Shenzhen Hospital, Shenzhen, China, ¹³The First Affiliated Hospital of Baotou Medical College, Baotou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵Jiangsu Provincial People's Hospital, Nanjing, China, ¹⁶The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹⁷Linyi People's Hospital, Linyi, China, ¹⁸Pingxiang People’s Hospital, PingXiang, China, ¹⁹The First Affiliated Hospital of Chengdu Medical College, Chengdu, China, ²⁰Xuzhou Medical University Affiliated Hospital, Xuzhou, China, ²¹Bestudy (Shanghai) Medical Technology Co., Ltd, Shanghai, China, ²²Clinical Department, Tianjin Hemay Pharmaceutical Co., Ltd., Tianjin, China, ²³Huashan Hospital Affiliated to Fudan University, Shanghai, China
Background/Purpose: Behçet's disease (BD) is a chronic and recurrent vascular inflammatory disease with major manifestations including oral ulcers, genital ulcers, skin damage and ophthalmitis, and…
Abstract Number: 1126 • ACR Convergence 2023
Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis
Ana Serrano-Combarro¹, Jose Luis Martin-Varillas², Raul Fernandez-Ramon³, Lara Sanchez-Bilbao⁴, Carmen Alvarez Reguera³, ELENA Aurrecoechea⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵HOSPITAL SIERRALLANA, Cantabria, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behcet's disease (BD) is a variable-vessel vasculitis with a high variability of clinical manifestations. The objective of our study was to identify clinical phenotypes…
Abstract Number: 1228 • ACR Convergence 2023
Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach
Caterina Matucci-Cerinic¹, helene Palluy², Sulaiman Al-Mayouf³, Paul Brogan⁴, Luca Cantarini⁵, Ahmet Gul⁶, Ozgur Kasapcopur⁷, Jasmin B. Kuemmerle-Deschner⁸, Seza Ozen⁹, david saadoun¹⁰, Farhad Shahram¹¹, Francesca Bovis¹², Eugenia mosci¹³, Nicolino Ruperto¹⁴, Marco Gattorno¹⁵ and Isabelle Kone-Paut¹⁶, ¹DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, ²Pediatric rheumatology and CEREMAIA, Bicêtre hospital, APHP, University of Paris Saclay, Paris, France, ³King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ⁴UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁸med.uni-tuebingen, Tübingen, Germany, ⁹Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁰Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire, F-75013, Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière., Neuilly sur Seine, France, ¹¹Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran, ¹²Dept of Health Sciences (DISSAL), University of Genoa, Genova, Italy, ¹³UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁴IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy, ¹⁵UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France
Background/Purpose: Behçet's disease (BD) is an autoinflammatory disease characterized by a variable vessel vasculitis. In the past, several criteria have been created for adult BD…
Abstract Number: 1248 • ACR Convergence 2023
Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry
Maria Vincenza Mastrolia¹, Caterina Matucci-Cerinic², Seza Ozen³, Ozgur Kasapcopur⁴, Carla Gaggiano⁵, Isabelle Kone-Paut⁶, Luca Cantarini⁵, Perrine Dusser⁷, Ümmüşen Kaya-Akça⁸, Mehmet Yildiz⁹, Juergen Brunner¹⁰, Giovanni Filocamo¹¹, Romina Gallizzi¹², Antonella Insalaco¹³, Serena Pastore¹⁴, Donato Rigante¹⁵, Judith Sanchez-Manubens¹⁶, Elena Tsitsami¹⁷, Marco Gattorno¹⁸ and Gabriele Simonini¹⁹, ¹NEUROFARBA Department, University of Florence, Florence, Italy, ²DINOGMI, University of Genoa; IRCCS Istituto Giannina Gaslini, UOC Rheumatology and autoinflammatory diseases, Genova, Italy, ³Hacettepe University Medical Faculty, Ankara, Turkey, ⁴Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁵Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena and Azienda Ospedaliero-Universitaria Senese [European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center], Siena, Italy, ⁶Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAIA, Bicêtre Hospital, APHP, University of Paris Saclay, Paris, France, ⁷Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, ⁸Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁹Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Instanbul, Turkey, ¹⁰Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, ¹¹Pediatric Immunorheumatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, MIlan, Italy, ¹²Department of Medical of Health Sciences, Magna Graecia University, Catanzaro, Italy, ¹³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ¹⁴Institute for Maternal and Child Health, RCCS “Burlo Garofolo", Trieste, Italy, ¹⁵Department of Life Sciences and Public Health, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, ¹⁶Pediatric Rheumatology, Section Pediatric Service, Parc Taulí Sabadell University Hospital, Institute for Research and Innovation I3PT, Sant Joan de Deu Hospital, Autonomous University of Barcelona, Barcelona, Spain, ¹⁷Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, ¹⁸UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹⁹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy
Background/Purpose: Arterial and venous thrombosis occurs in 6.6 to 38.4% of pediatric Behçet disease (BD) and cerebral sinus is one of the most involved districts.…
Abstract Number: 1554 • ACR Convergence 2023
Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study
Audrey Hermant¹, Yann Nguyen², Fleur Cohen³, Antoine Baudet⁴, Alban DEROUX⁵, Vincent Poindron⁶, Cécile-Audrey Durel⁷, Nicolas Girszyn⁸, Noémie Le Gouellec⁹, Benedicte Rouviere¹⁰, Helder Gil¹¹, Francois Maurier¹², Nicolas Noel¹³, Loic Raffray¹⁴, Hubert De Boysson¹⁵, Benoit Faucher¹⁶, Bertrand Godeau¹⁷, Pierre Lozach¹⁸, Claude Bachmeyer¹⁹, Alice Berezne⁴, Gilles Blaison²⁰, Brice Castel²¹, Guillaume Gondran²², Matthieu Groh²³, Stéphane Giorgiutti²⁴, Jeremy Keraen²⁵, Julie Magnant²⁶, Sebastien Monnier²⁷, Philippe Blanche²⁸, Dominique Monnet²⁹, Antoine Brezin²⁹ and Benjamin Terrier³⁰, ¹Hopital Cochin, Paris, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Sorbonne Université, Paris, France, ⁴CH Annecy, Annecy, France, ⁵CHU de Grenoble, Grenoble, France, ⁶Strasbourg, Strasbourg, France, ⁷CHU Lyon, Lyon, France, ⁸Rouen, Rouen, France, ⁹CH Valenciennes, Valenciennes, France, ¹⁰CHU Brest, Brest, France, ¹¹CHU Besancon, Besançon, France, ¹²CH Metz, Metz, France, ¹³CHU Bicetre, Le Kremlin-Bicêtre, France, ¹⁴CHU la Réunion, La Réunion, France, ¹⁵CHU Caen, Caen, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Henri Mondor, Créteil, France, ¹⁸CH Le Mans, Le Mans, France, ¹⁹CHU Tenon, Paris, France, ²⁰Hôpital Louis PASTEUR, Colmar, France, ²¹CH Tarbes, Tarbes, France, ²²CHU Limoges, Limoges, France, ²³National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, ²⁴CHRU Strasbourg, Strasbourg, France, ²⁵CH Quimper, Quimper, France, ²⁶CHU Tours, Tours, France, ²⁷CH Versailles, Versailles, France, ²⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²⁹CHU Cochin, Paris, France, ³⁰Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: The management of severe ocular involvement in Behçet's disease (BD) is an important issue with major functional implications due to the risk of blindness.…
Abstract Number: 1555 • ACR Convergence 2023
Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behçet Syndrome
Musab Ozturk¹, Sinem Nihal Esatoglu², Ibrahim Hatemi³, Aykut Ferhat Celik³, Osman Aykan Kargin⁴, Ahmet Oz⁴, Erkan Yilmaz⁵, Didar Ucar⁶, Melike Melikoglu², Hasan Yazici⁷, Ibrahim Adaletli⁴ and Gulen Hatemi², ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Radiology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Tissue Typing Laboratory, Istanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁷Academic Hospital, Istanbul, Turkey
Background/Purpose: Controlled studies have shown that radiographic sacroiliitis was not increased in Behçet syndrome (BS), compared to other inflammatory diseases. However, gastrointestinal involvement of Behçet…
Abstract Number: 1556 • ACR Convergence 2023
Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome
Sinem Nihal Esatoglu¹, Sabriye Guner¹, Sevim Guler², Gulen Hatemi¹, Nuray Kepil³, Yusuf Ziya Erzin⁴, Aykut Ferhat Celik⁴ and Ibrahim Hatemi⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…
Abstract Number: 1557 • ACR Convergence 2023
De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome
Sinem Nihal Esatoglu¹, Ozge Sonmez², Didar Ucar³, Elif Kaymaz⁴, Yesim Ozguler⁵, Serdal Ugurlu⁶, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko⁷, Vedat Hamuryudan¹, Ugur Uygunoglu⁸, Zekayi Kutlubay⁹ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁶Istanbul University-Cerrahpasa, Istanbul, Turkey, ⁷Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁸Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey, ⁹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Dermatology, Istanbul, Turkey
Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet's syndrome…
Abstract Number: 1558 • ACR Convergence 2023
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Didar Ucar¹, Basak Ecem Bircan², Nigar Rustamli², Bilge Batu Oto¹, Vedat Hamuryudan³, Sinem Nihal Esatoglu³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
Abstract Number: 1559 • ACR Convergence 2023
Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease
Nuria Barroso-Garcia¹, Jose Luis Martin-Varillas², Lara Sanchez-Bilbao³, Ivan Ferraz Amaro⁴, Vanesa Calvo Río⁵, Alfredo Adán⁶, Inés Hernanz-Rodriguez⁷, Emma Beltran-Catalan⁸, David Diaz-Valle⁹, Marisa Hernandez-Garfella¹⁰, Lucia Martinez-Costa¹¹, Manuel Diaz-Llopis¹², Jose M Herreras¹³, Olga Maiz-Alonso¹⁴, Ignacio Torre-Salaberri¹⁵, Antonio Atanes Sandoval¹⁶, Santos Insua-Vilariño¹⁷, Raquel Almodovar¹⁸, Patricia Fanlo-Mateo¹⁹, Juan Ramon De Dios²⁰, Angel Garcia-Aparicio²¹, Sergio rodriguez-Montero²², Vega Jovani²³, Patricia Moya²⁴, Eva Peña Sainz-Pardo²⁵, Jose Luis Hernandez²⁶ and Ricardo Blanco²⁷, ¹Hospital Universitario Puerta del Mar, Cadiz, Spain, ²Hospital de Laredo, Laredo, Spain, ³Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵Valdecilla Hospital, Santander, Spain, ⁶Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁷Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, ⁸HOSPITAL DEL MAR, Barcelona, Spain, ⁹Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, ¹¹Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹²Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, ¹³Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, ¹⁴University Hospital Donostia, San Sebastian, Spain, ¹⁵Hospital Universitario de Basurto, Bilbao, Spain, ¹⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, ¹⁷Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, ¹⁸Alcorcón Foundation University Hospital, Madrid, Spain, ¹⁹Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, ²⁰Osakidetza, Vitoria, Spain, ²¹Hospital Universitario de Toledo, Toledo, Spain, ²²Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, ²³Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, ²⁴Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ²⁵Pediatric, Hospital 12 de Octubre, Madrid, Spain, ²⁶Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
Abstract Number: 127 • 2023 Pediatric Rheumatology Symposium
What’s in a Name? A20 Protein Expression in an in Vitro Model of A20 Haploinsufficiency
Patricia Pontes Aires¹, DANIELA GERENT PETRY PIOTTO¹, Andre Cunha¹, Sandro Perazzio² and Maria Teresa Terreri³, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade de So Paulo; Fleury Laboratories, São Paulo, Brazil, ³UNIFESP, São Paulo, Brazil
Background/Purpose: Tumor necrosis factor alpha (TNF-alpha) induced protein 3 gene, or TNFAIP3, encodes the A20 protein, an important regulator of the NF-κB pathway. Since its…
Abstract Number: 1264 • ACR Convergence 2022
Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
Kerem Abacar¹, Rabia Ergelen², Fatma Temiz², Yasin Yildiz², Tulin Ergun³, Haner Direskeneli⁴ and Fatma Alibaz-Oner¹, ¹Marmara University, Rheumatology, Istanbul, Turkey, ²Marmara University, School of Medicine, Departmant of Internal Medicine, Istanbul, Turkey, ³Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: We reported the first controlled ultrasound study showing increased common femoral vein(CFV) thickness in Behçet's Disease(BD),1 and showed that this is a distinctive feature…
Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Alba Herrero-Morant¹, José Luis Martín-Varillas², Santos Castañeda³, Olga Maiz⁴, Julio Sánchez-Martín⁵, Norberto Ortego⁶, Enrique Raya⁷, Águeda Prior-Español⁸, Clara Moriano⁹, Rafael Melero¹⁰, Genaro Graña-Gil¹¹, Ana Urruticoechea¹², Angel Ramos¹³, Marta Loredo-Martínez¹⁴, Eva Salgado-Pérez¹⁵, Francisca Sivera¹⁶, Ignacio Torre¹⁷, F. Javier Narváez¹⁸, Jose Luis Andreu¹⁹, Olga Martinez²⁰, Ricardo Gómez-de la Torre²¹, Sabela Fernandez-Aguado²², Susana Romero Yuste²³, iñigo Gonzalez-Mazon⁵, Carmen Alvarez Reguera⁵, David Martínez-López⁵, José Luis Hernández⁵, Miguel Ángel González-Gay²⁴ and Ricardo Blanco²⁵, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital de Laredo, Laredo, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁴Hospital Universitario de Donostia, San Sebastián, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Medicine Department, Universidad de Granada, Granada, Spain, ⁷Hospital San Cecilio, Granada, Spain, ⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁹Complejo Asistencial Universitario de León, León, Spain, ¹⁰Complexo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Hospital Universitario de A Coruña, A Coruña, Spain, ¹²Hospital Can Misses, Ibiza, Spain, ¹³Complejo Hospitalario de Soria, Soria, Spain, ¹⁴Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁵Complejo Hospitalario Universitario de Ourense, Santiago de Composte, Spain, ¹⁶Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹⁷Hospital de Basurto, Basurto, Spain, ¹⁸Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²⁰Hospital Clínico Universitario de Salamanca, Zamora, Spain, ²¹Hospital Universitario Central de Asturias, Oviedo, Spain, ²²Hospital Universitario de Cabueñes, Gijon, Spain, ²³Complexo Hospitalario Universitario, Pontevedra, Spain, ²⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…
Abstract Number: 1557 • ACR Convergence 2022
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
Belén Atienza-Mateo¹, Alfonso del Peral-Fanjul², Veronica Pulito-Cueto³, Diana Prieto-Peña¹, Miguel Ángel González-Gay⁴ and Ricardo Blanco⁵, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain, Spain, ³IDIVAL, Santander, Spain, ⁴Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Ocular and mucocutaneous manifestations of Behçet's disease (BD) are globally recognized and widely studied [Arthritis Rheumatol. 2019 Dec;71(12):2081-2089, Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl…
Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Alba Herrero-Morant¹, Carmen Alvarez Reguera², Lara Sánchez-Bilbao², David Martínez-López², guillermo Suárez-Amorin², Raúl fernández-ramón², José Luis Martín-Varillas³, Cristina Mata⁴, Miguel Ángel González-Gay⁵ and Ricardo Blanco⁶, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Cantabria, Spain, ⁴Hospital Laredo, Santander, Spain, ⁵Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].